KR910005852A - 이중 제피 과립 - Google Patents

이중 제피 과립 Download PDF

Info

Publication number
KR910005852A
KR910005852A KR1019900014101A KR900014101A KR910005852A KR 910005852 A KR910005852 A KR 910005852A KR 1019900014101 A KR1019900014101 A KR 1019900014101A KR 900014101 A KR900014101 A KR 900014101A KR 910005852 A KR910005852 A KR 910005852A
Authority
KR
South Korea
Prior art keywords
granules
hydrophilic
resistant
coating
coated
Prior art date
Application number
KR1019900014101A
Other languages
English (en)
Inventor
비르트 다그마르
부커 크리스티안
Original Assignee
베르너 발데그
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데그, 시바-가이기 에이지 filed Critical 베르너 발데그
Publication of KR910005852A publication Critical patent/KR910005852A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

내용 없음

Description

이중 제피 과립
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 친수성이며 탄성이 있는 내부 피막 및 위액에 내성을 나타내고 장액에 용해되는 외부 피막으로 이루어지는 이중 제피된 이나트륨 3-아미노-1-하이드록시프로판-1,1-디포스포네이트(이나트륨 파미드로네이트)를 비경구 투여하기 위한 조절방출성 과립.
  2. 제1항에 있어서, 친수성이고 탄성이 있는 내부 피막 및 위액에 내성을 나타내고 장액에 용해되는 외부 피막으로 제피된 구형 펠릿으로 제조된 과립.
  3. 제2항에 있어서, 직경 약0.3 내지 1.5mm인 구형 펠릿으로 제조된 과립.
  4. 제2항에 있어서, 직경 약0.5 내지 1.25mm인 구형 펠릿으로 제조된 과립.
  5. 제1항에 있어서, 친수성이며 탄성이 있는 셀룰로즈 에테르의 피막으로 제피된 과립.
  6. 제5항에 있어서, 친수성이며 탄성이 있는 하이드록시 프로필메틸셀룰로즈의 피막으로 제피된 과립.
  7. 제1항에 있어서, 위액에 내성을 나타내며 장액에 용해되는 C1-C4알킬 그룹에 의해 부분적으로 에스테르화된 아크릴산-메타크릴산 공중합체의 외부 피막으로 제피된 과립.
  8. 제7항에 있어서, 위액에 내성을 나타내며 장액에 용해되는 메틸 및/또는 에틸 그룹에 의해 부분적으로 에스테르화된 아크릴산-메타크릴산 공중합체의 외부 피막으로 제피된 과립.
  9. 친수성이며 탄성이 있는 내부 피막 및 위액에 내성을 나타내고 장액에 용해되는 외부 피막으로 제피된 구형 펠릿으로 제조된 이중 제피 서방성 과립을 함유하는 캡슐 또는 샤세 형태의 이나트륨 파미드로네이트의 결정성 5수화물을 경구 투여하기 위한 고상 약제학적 투여형.
  10. 이나트륨 파미드로네이트를 과립화하고, 과립을 친수성이며 탄성이 있는 내부 피막으로 제피한 다음, 위액에 내성을 나타내고 장액에 용해되는 외부 피막으로 제피함을 특징으로 하여 제1항에 따르는 과립을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900014101A 1989-09-07 1990-09-07 이중 제피 과립 KR910005852A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH0324589-3 1989-09-07
CH324589 1989-09-07

Publications (1)

Publication Number Publication Date
KR910005852A true KR910005852A (ko) 1991-04-27

Family

ID=4251793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900014101A KR910005852A (ko) 1989-09-07 1990-09-07 이중 제피 과립

Country Status (21)

Country Link
US (1) US5096717A (ko)
EP (1) EP0421921B1 (ko)
JP (1) JP3009713B2 (ko)
KR (1) KR910005852A (ko)
AT (1) ATE104856T1 (ko)
AU (1) AU623036B2 (ko)
CA (1) CA2024631C (ko)
DD (1) DD298049A5 (ko)
DE (1) DE59005517D1 (ko)
DK (1) DK0421921T3 (ko)
ES (1) ES2052228T3 (ko)
FI (1) FI93169C (ko)
HU (1) HU207447B (ko)
IE (1) IE63668B1 (ko)
IL (1) IL95558A (ko)
MX (1) MX22254A (ko)
NO (1) NO176646C (ko)
NZ (1) NZ235187A (ko)
PH (1) PH27186A (ko)
PT (1) PT95209B (ko)
ZA (1) ZA907100B (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
WO1993001800A1 (en) * 1991-07-24 1993-02-04 Thomas Sai Ying Ko Therapeutic compositions and methods
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687291B1 (fr) * 1992-02-17 1994-06-03 Sfbd Vivis Aliment pour sportif et son procede de fabrication.
TW237386B (ko) * 1992-04-15 1995-01-01 Ciba Geigy
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
DE4236090C1 (de) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmazeutische Zubereitung für die Fluoridionen-Versorgung
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
HUP0004625A1 (hu) * 1997-06-11 2001-06-28 The Procter & Gamble Co. Az emésztőcsatorna felső szakaszának fokozott biztonságot nyújtó filmbevonatos tabletta
DE69834195T2 (de) 1997-07-02 2007-03-29 Euro-Celtique S.A. Stabilisierte tramadol formulierungen mit verzögerter freisetzung
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
JP2007519608A (ja) * 2003-09-19 2007-07-19 ペンウェスト ファーマシューティカルズ カンパニー 時間治療用剤形
KR100782918B1 (ko) * 2003-09-19 2007-12-07 펜웨스트 파머슈티칼즈 컴파니 지연 방출성 제형
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
EP1781258A1 (en) * 2004-08-20 2007-05-09 Mepha AG Formulations of bisphosphonates
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
EP2270131A1 (en) * 2005-05-31 2011-01-05 The Iams Company Feline probiotic lactobacilli
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
PL2124966T3 (pl) 2007-02-01 2016-01-29 Iams Europe B V Sposób zmniejszania reakcji zapalnej i stresu u ssaków za pomocą antymetabolitów glukozy, awokado lub ekstraktów awokado
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8663671B2 (en) 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
IL95558A0 (en) 1991-06-30
HUT59008A (en) 1992-04-28
NO903892L (no) 1991-03-08
ATE104856T1 (de) 1994-05-15
NZ235187A (en) 1992-03-26
DD298049A5 (de) 1992-02-06
PT95209B (pt) 1998-06-30
IE63668B1 (en) 1995-05-31
IL95558A (en) 1995-08-31
CA2024631C (en) 2000-11-21
NO176646B (no) 1995-01-30
DE59005517D1 (de) 1994-06-01
HU905812D0 (en) 1991-03-28
FI904341A0 (fi) 1990-09-03
PT95209A (pt) 1991-05-22
EP0421921B1 (de) 1994-04-27
NO903892D0 (no) 1990-09-06
DK0421921T3 (da) 1994-05-30
AU623036B2 (en) 1992-04-30
IE903239A1 (en) 1991-03-13
HU207447B (en) 1993-04-28
AU6228390A (en) 1991-03-14
US5096717A (en) 1992-03-17
JPH0399016A (ja) 1991-04-24
MX22254A (es) 1993-12-01
JP3009713B2 (ja) 2000-02-14
CA2024631A1 (en) 1991-03-08
FI93169B (fi) 1994-11-30
PH27186A (en) 1993-04-16
FI93169C (fi) 1995-03-10
ZA907100B (en) 1991-05-29
NO176646C (no) 1995-05-10
ES2052228T3 (es) 1994-07-01
EP0421921A1 (de) 1991-04-10

Similar Documents

Publication Publication Date Title
KR910005852A (ko) 이중 제피 과립
CA1172570A (en) Orally administrable pharmaceutical compositions
FI78835B (fi) Foerfarande foer framstaellning av en ny dipyridamol-retardform.
AU639988B2 (en) Taste masking of ibuprofen by fluid bed coating
PT825858E (pt) Capsulas de libertacao dependente do tempo contendo acidos poliinsaturados omega-3 para o tratamento da doenca inflamatoria do intestino
BE905518A (fr) Comprime pharmaceutique enrobe contenant de l'ester 1-acetoxyethylique de la cefuroxime et procede de preparation de celui-ci.
US4981695A (en) Composition comprising L-dopa
LV12399A (lv) Uzlabotas vienreiz diena lietojamas pulsejosas miniciklina mogades sistemas
KR870003778A (ko) 신규 약제의 제조방법
KR860001591A (ko) 펠렛 제제물 및 그의 제조방법
CA2025703A1 (en) Pulsatile once-a-day delivery systems for minocycline
IE59200B1 (en) Therapeutic compositions for oral administration
US4808416A (en) Preparation of a slow-release drug
Christensen et al. Comparative bioavailability of 5‐aminosalicylic acid from a controlled release preparation and an azo‐bond preparation
US3126320A (en) Enteric-coated tablets of dextran sul-
JPS60208918A (ja) 治療作用をもつ新規な、スルホン樹脂を含有する医薬及びその製造方法
KR910019609A (ko) 지속성 세팔렉신과립제의 제조방법
KR930007447A (ko) 산불안정 화합물의 경구용 약제

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application